Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's D&A?
- Allogene Therapeutics (ALLO) reported D&A of $2.87M in Q1 2026.
- How has Allogene Therapeutics's D&A changed year-over-year?
- Allogene Therapeutics's D&A decreased by 7.4% year-over-year, from $3.1M to $2.87M.
- What is the long-term trend for Allogene Therapeutics's D&A?
- Over 4 years (2021 to 2025), Allogene Therapeutics's D&A has grown at a 4.3% compound annual growth rate (CAGR), from $10.45M to $12.36M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Allogene Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude